La Jolla Pharmaceutical Company   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: San Diego CA United States (1989)
Status: Left NME R&D (2020)

Organization Overview

First Clinical Trial
2002
NCT00035308
First Marketed Drug
2017
angiotensin ii
First NDA Approval
2017
angiotensin ii
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Chief Medical Officer, La Jolla Pharmaceutical Company | LA JOLLA PHARMA | La Jolla Pharmaceutical Company